Observational studyNeurosurgical review2025
Parkinson's disease and deep brain stimulation of the subthalamic nucleus (STN-DBS): long-term disease evaluation and neuropsychological outcomes in a 9-year matched-controlled study.
Observational study in Neurosurgical review, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Matched-controlled long-term disease evaluation and neuropsychological outcomes derived from deep brain stimulation of the subthalamic nucleus (STN-DBS) in Parkinson´s disease (PD) are lacking, with inconsistent results regarding the cognitive impact of this procedure. Here we study the long-term effects associated to DBS comparing outcomes with a matched control group. A prospective observational study of 40 patients with PD with bilateral STN-DBS, with a mean follow-up of 9 (6-12) years was conducted. Disease evaluation was performed using the UPDRS-III, UPDRS-II, Hoehn-Yahr, and Schwab-England scales. Neuropsychological assessments were achieved utilizing the MMSE, DRS, RAVLT, BVRT, Stroop, and verbal fluency tests. A control group was used for comparison. Statistical analysis was performed with SPSSv.26. 40 patients were included, with a mean age of 62.8 ± 8.5 at the time of intervention. An improvement in motor symptoms of 48.6% (p < 0.001) and a reduction in LED of 58.6% (p < 0.001) was observed. No significant differences were observed in the MMSE (p = 0.414), DRS (p = 0.251), memory or interference assessments. A worsening in the construction subscale of DRS (p < 0.05) and in verbal fluency (phonemic and semantic) (p < 0.05) was observed. A head-to-head comparison showed significant differences between groups. An age ≤ 60 years was associated with a good long-term clinical prognosis (p = 0.019;OR = 6.75). STN-DBS is an effective and safe therapeutic option for the control of motor symptoms. However, it is associated with a selective deterioration in some cognitive functions in the long term. This study comprehensively evaluates STN-DBS in Parkinson´s disease in the long term, with findings that should be considered when indicating surgery in PD patients.
Indexed as
Identifiers
39847189What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.